Search in:

OncoTargets and Therapy Volume 10, 2017 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial

Josep Tabernero1 Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, SpainCorrespondence[email protected]

Volker Kunzmann2 Medizinische Klinik und Poliklinik II, University of Würzburg, Würzburg, Germany

Werner Scheithauer3 Medizinische Universität Wien, Wien, Austria

Michele Reni4 San Raffaele Scientific Institute, Milan, Italy

Jack Shiansong Li5 Celgene Corporation, Summit, NJ, USA

Stefano Ferrara6 Celgene Corporation, Boudry, Switzerland

Kamel Djazouli7 Celgene Corporation, Paris, France

show all

Pages 591-596 | Published online: 02 Feb 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (18)

Juraj Prejac, Dora Tomek Hamzić, Nikša Librenjak, Irma Goršić, Domina Kekez & Stjepko Pleština. (2022) The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence. Medicine 101:39, pages e30566.
Crossref

Haidong Zhang, Hui Dong, Zheng Pan, Xuanlong Du, Shiwei Liu, Wenjing Xu & Yewei Zhang. (2022) Risk factors and predictive nomograms for early death of patients with pancreatic cancer liver metastasis: A large cohort study based on the SEER database and Chinese population. Frontiers in Oncology 12.
Crossref

Mohd Sajid Ali & Hamad A. Al-Lohedan. (2022) Experimental and Computational Investigation on the Interaction of Anticancer Drug Gemcitabine with Human Plasma Protein: Effect of Copresence of Ibuprofen on the Binding. Molecules 27:5, pages 1635.
Crossref

Parthasarathy Seshacharyulu, Sushanta Halder, Ramakrishna Nimmakayala, Satyanarayana Rachagani, Sanjib Chaudhary, Pranita Atri, Ramakanth Chirravuri-Venkata, Michel M. Ouellette, Joseph Carmicheal, Shailendra K. Gautam, Raghupathy Vengoji, Shuo Wang, Sicong Li, Lynette Smith, Geoffrey A. Talmon, Kelsey Klute, Quan Ly, Bradley N Reames, Jean L Grem, Lyudmyla Berim, James C Padussis, Sukhwinder Kaur, Sushil Kumar, Moorthy P. Ponnusamy, Maneesh Jain, Chi Lin & Surinder K Batra. (2022) Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. eBioMedicine 75, pages 103772.
Crossref

Sara De Dosso, Alexander R. Siebenhüner, Thomas Winder, Alexander Meisel, Ralph Fritsch, Christoforos Astaras, Petr Szturz & Markus Borner. (2021) Treatment landscape of metastatic pancreatic cancer. Cancer Treatment Reviews 96, pages 102180.
Crossref

M. Tempero, D.-Y. Oh, J. Tabernero, M. Reni, E. Van Cutsem, A. Hendifar, D.-T. Waldschmidt, N. Starling, J.-B. Bachet, H.-M. Chang, J. Maurel, R. Garcia-Carbonero, S. Lonardi, L.M. Coussens, L. Fong, L.C. Tsao, G. ColeJrJr, D. James & T. Macarulla. (2021) Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Annals of Oncology 32:5, pages 600-608.
Crossref

Marina Macchini, Marta Chiaravalli, Chiara Pircher, Silvia Zanon, Umberto Peretti, Elena Mazza, Maria Maddalena Valente, Clara Fugazza, Luca Gianni & Michele Reni. (2021) Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. Digestive and Liver Disease 53:1, pages 117-121.
Crossref

Michele Reni. (2021) APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinoma. The Lancet Oncology 22:1, pages 10-11.
Crossref

Stefano Crippa, Roberto Cirocchi, Matthew J. Weiss, Stefano Partelli, Michele Reni, Christopher L. Wolfgang, Thilo Hackert & Massimo Falconi. (2020) A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates in Surgery 72:1, pages 39-45.
Crossref

Yung‐Jue Bang, Chung‐Pin Li, Kyung‐Hun Lee, Chang‐Fang Chiu, Joon Oh Park, Yan‐Shen Shan, Jun Suk Kim, Jen‐Shi Chen, Hyun‐Jeong Shim, Kun‐Ming Rau, Hye Jin Choi, Do‐Youn Oh, Bruce Belanger & Li‐Tzong Chen. (2019) Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study. Cancer Science 111:2, pages 513-527.
Crossref

Henu K. Verma, Praveen K. Kampalli, Saikrishna Lakkakula, Gayathri Chalikonda, Lakkakula V.K.S. Bhaskar & Smaranika Pattnaik. (2020) A Retrospective Look at Anti-EGFR Agents in Pancreatic Cancer Therapy. Current Drug Metabolism 20:12, pages 958-966.
Crossref

Susanna Hegewisch-Becker, Ali Aldaoud, Thomas Wolf, Beate Krammer-Steiner, Hartmut Linde, Renate Scheiner-Sparna, David Hamm, Martina Jänicke & Norbert Marschner. (2019) Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. International Journal of Cancer 144:5, pages 981-990.
Crossref

L.V.K.S. Bhaskar & L. Saikrishna. 2019. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy 175 195 .

Ines Lohse, Erin Wildermuth & Shaun P. Brothers. (2018) Naturally occurring compounds as pancreatic cancer therapeutics. Oncotarget 9:83, pages 35448-35457.
Crossref

Rosemary Young, Paul Mainwaring, Philip Clingan, Francis Xavier Parnis, Gholamreza Asghari, Philip Beale, Abdalla Aly, Marc Botteman, Alfredo Romano, Stefano Ferrara, Sandra Margunato-Debay & Marion Harris. (2018) nab -Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial . Asia-Pacific Journal of Clinical Oncology 14:5, pages e325-e331.
Crossref

David Malka, Ivan Borbath & Thierry Conroy. (2018) Chemotherapy for pancreatic cancer: the rise of multidrug regimens. The Lancet Gastroenterology & Hepatology 3:10, pages 659-660.
Crossref

Michele Reni, Silvia Zanon, Umberto Peretti, Marta Chiaravalli, Diletta Barone, Chiara Pircher, Gianpaolo Balzano, Marina Macchini, Silvia Romi, Elena Gritti, Elena Mazza, Roberto Nicoletti, Claudio Doglioni, Massimo Falconi & Luca Gianni. (2018) Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. The Lancet Gastroenterology & Hepatology 3:10, pages 691-697.
Crossref

Davide Pastorelli, Aline S.C. Fabricio, Petros Giovanis, Simona D'Ippolito, Pasquale Fiduccia, Caterina Soldà, Andrea Buda, Cosimo Sperti, Romeo Bardini, Gianfranco Da Dalt, Giulia Rainato, Massimo Gion & Fulvio Ursini. (2018) Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial. Pharmacological Research 132, pages 72-79.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial

Articles from other publishers (18)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial

Citations (18)

Articles from other publishers (18)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date